v2.4.0.8
Summary of Transactions in Stock-Based Compensation Plans (Details) (USD $)
9 Months Ended 12 Months Ended 2 Months Ended 9 Months Ended 12 Months Ended 9 Months Ended 12 Months Ended 9 Months Ended 12 Months Ended
Dec. 31, 2012
Sep. 30, 2013
Shares Available For Grant
Dec. 31, 2012
Shares Available For Grant
Dec. 31, 2011
Shares Available For Grant
Dec. 31, 2010
Shares Available For Grant
Mar. 01, 2013
RSUs
Sep. 30, 2013
RSUs
Dec. 31, 2012
RSUs
Dec. 31, 2011
RSUs
Sep. 30, 2013
Stock Options
Dec. 31, 2012
Stock Options
Dec. 31, 2011
Stock Options
Dec. 31, 2010
Stock Options
Sep. 30, 2013
Restricted Stock
Dec. 31, 2012
Restricted Stock
Dec. 31, 2011
Restricted Stock
Dec. 31, 2010
Restricted Stock
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Including Options, Shares Available for Grant [Roll Forward]                                  
Balance, beginning of period   14,643,932 15,752,370 4,280,180 7,285,606                        
Granted   (924,312) (1,504,410) (1,643,348) (3,423,066)                        
Shares issued for director compensation       (31,166)                          
Cancelled   177,174 395,972 346,704 417,640                        
Additional shares authorized       12,800,000                          
Balance, end of period   13,896,794 14,643,932 15,752,370 4,280,180                        
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]                                  
Balance, beginning of period 9,355,070                 9,355,070 13,078,092 16,147,930 18,658,814        
Granted                         3,423,066        
Exercised                   (2,143,544) (3,446,472) (2,768,038) (5,516,310)        
Cancelled                   (79,920) (276,550) (301,800) (417,640)        
Balance, end of period 9,355,070                 7,131,606 9,355,070 13,078,092 16,147,930        
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Roll Forward]                                  
Balance, weighted average exercise price, beginning of period $ 6.90                 $ 6.90 $ 6.47 $ 6.14 $ 4.41        
Granted, weighted average exercise price                         $ 9.98        
Exercised, weighted average exercise price                   $ 6.37 $ 5.13 $ 4.31 $ 2.53        
Cancelled, weighted average exercise price                   $ 8.80 $ 8.30 $ 8.44 $ 8.06        
Balance, weighted average exercise price, end of period $ 6.90                 $ 7.04 $ 6.90 $ 6.47 $ 6.14        
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Roll Forward]                                  
Balance, weighted average grant date fair value, beginning of period           $ 14.02 $ 14.02 $ 11.80           $ 9.47 $ 9.49 $ 9.50 $ 9.50
Granted, weighted average grant date fair value             $ 22.18 $ 15.86 $ 11.80                
Vested, weighted average grant date fair value             $ 15.04 $ 13.09 $ 11.84         $ 9.54 $ 9.51 $ 9.51 $ 9.51
Cancelled, weighted average grant date fair value             $ 16.14 $ 14.03 $ 11.77                
Balance, weighted average grant date fair value, end of period             $ 16.63 $ 14.02 $ 11.80         $ 9.30 $ 9.47 $ 9.49 $ 9.50
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]                                  
Balance, beginning of period           2,351,362 2,351,362 1,433,582           116,000 212,000 308,000 404,000
Granted           594,700 924,312 1,504,410 1,643,348                
Vested             (593,671) (467,208) (164,862)         (86,000) (96,000) (96,000) (96,000)
Cancelled             (97,254) (119,422) (44,904)                
Balance, end of period             2,584,749 2,351,362 1,433,582         30,000 116,000 212,000 308,000